James P. Hartman has been appointed vice president of medical dermatology at Merz, Inc. (a division of Merz Pharma Group, www.merz.com). Hartman will be responsible for the company's Medical and OTC/OTX dermatology business unit, which includes Naftin (naftifine hydrochloride) and Mederma.
“Jim has a proven track record when it comes to developing and commercializing pharmaceutical and OTC/OTX products,” said Bill Humphries, president/CEO of Merz. “We are extremely pleased to have him join the Merz team and are confident he will make immediate and important contributions to the continued growth of our medical dermatology business and the company as a whole."
Prior to joining Merz, Hartman was vice president, global marketing & business development, at Obagi Medical Products. Previously, he was senior vice president, U.S. commercial operations, and vice president of U.S. marketing for Stiefel Laboratories. Hartman also has held senior-level positions with Allergan and SmithKline Beecham (now GlaxoSmithKline).
Merz has also promoted Katrina Church to vice president, chief compliance officer, effective July 1, 2012. Church will be responsible for providing strategic and operational leadership relating to compliance issues.
Church graduated magna cum laude from Duke University and obtained her juris doctor from the New York University School of Law. Prior to joining Merz in 2009, she was employed by Connetics, where she served as general counsel. Following the acquisition of Connetics by Stiefel Laboratories in 2006, she provided legal consulting services to Stiefel.
“Katrina brings extensive experience and a wealth of legal knowledge in pharmaceutical regulatory compliance to her new role,” said Humphries. “Merz, Inc. is committed to a tight set of core values that foster a positive, productive and unified work environment. Katrina plays a vital role in ensuring that we uphold the highest standards and values in this dynamic regulatory environment. We look forward to working with her on the many compliance requirements facing pharmaceutical companies today.”